Resting heart rate is a heritable trait correlated with life span. Little is known about the genetic contribution to resting heart rate and its relationship with mortality. We performed a genome-wide association discovery and replication analysis starting with 19.9 million genetic variants and studying up to 265,046 individuals to identify 64 loci associated with resting heart rate (P < 5 × 10 −8 ); 46 of these were novel. We then used the genetic variants identified to study the association between resting heart rate and all-cause mortality. We observed that a genetically predicted resting heart rate increase of 5 beats per minute was associated with a 20% increase in mortality risk (hazard ratio 1.20, 95% confidence interval 1.11-1.28, P = 8.20 × 10 −7 ) translating to a reduction in life expectancy of 2.9 years for males and 2.6 years for females. Our findings provide evidence for shared genetic predictors of resting heart rate and all-cause mortality.
Resting heart rate is a heritable trait correlated with life span. Little is known about the genetic contribution to resting heart rate and its relationship with mortality. We performed a genome-wide association discovery and replication analysis starting with 19.9 million genetic variants and studying up to 265,046 individuals to identify 64 loci associated with resting heart rate (P < 5 × 10 −8 ); 46 of these were novel. We then used the genetic variants identified to study the association between resting heart rate and all-cause mortality. We observed that a genetically predicted resting heart rate increase of 5 beats per minute was associated with a 20% increase in mortality risk (hazard ratio 1.20, 95% confidence interval 1.11-1.28, P = 8.20 × 10 −7 ) translating to a reduction in life expectancy of 2.9 years for males and 2.6 years for females. Our findings provide evidence for shared genetic predictors of resting heart rate and all-cause mortality.
Among mammals there is an inverse semilogarithmic relationship between resting heart rate and life expectancy; only humans show deviation from this line 1, 2 . In humans, resting heart rate is a wellestablished predictor of overall mortality in the general population [3] [4] [5] [6] [7] [8] as well as in patients with hypertension 9 , coronary artery disease (CAD) 10 and heart failure 11 . The association of heart rate with life expectancy or risk does not provide sufficient evidence for a shared or causal relationship. Heart rate is regulated by complex interactions of biological systems, including the autonomous nervous and hormonal systems 12 . In addition, resting heart rate is associated with many other cardiovascular risk factors, including blood pressure, smoking, glucose metabolism, blood lipid and C-reactive protein levels, metabolic syndrome, body mass index and diabetes mellitus [13] [14] [15] [16] . In some conditions, including heart failure, reduction of heart rate has been shown to lead to event reduction, providing evidence that heart rate is a modifiable, causal risk factor and not just a risk marker or a reflection of comorbidities 11 . However, in patients with CAD and hypertension, β-adrenergic receptor-blocking agents (beta-blockers) are not associated with lower risk of cardiovascular events beyond their effect on blood pressure 17, 18 ; in patients with permanent atrial fibrillation, lenient rate control is as effective as strict rate control 19 , and heart rate reduction with ivabradine does not improve outcomes in patients with CAD 20 , though it does improve outcomes in patients with heart failure 21 . No mechanistic explanation linking higher resting heart rate with increased mortality has emerged.
We performed a genome-wide association study (GWAS) on 134,251 individuals participating in UK Biobank 22 to further our understanding of genes that influence resting heart rate. The average participant age was 56.6 years (interquartile range (IQR) 50-63), and 47.2% of the participants were male ( Table 1 and Supplementary  Table 1 ). The median duration of follow up for mortality was 4.9 years (IQR 4.3-5.5 years), and there were 2,364 mortality events in total. The incidence rate was 3.6 events (95% CI 3.4-3.7 events) per 1,000 person-years of follow up.
We identified genetic variants at 76 loci associated with resting heart rate (P < 5 × 10 −8 ) (Fig. 1, Table 2 , Supplementary Figs. 1-3 and Supplementary Table 2) ; 64 of these loci were replicated in 130,795 individuals from 4 cohorts, and 46 loci have not been previously reported as associated with resting heart rate 23 . The genetic variants at the 64 loci were well imputed, with an information score > 0.9, except one (rs11183443), which had an information measure of 0.30. At 11 loci we found evidence for multiple independent associations with resting heart rate in conditional analyses (Supplementary Table 3 ). As expected, the magnitudes of the associations were small and ranged from 0.2 to 1.1 beats per minute (bpm) per effect allele. Collectively, the total variance explained by the 64 loci for resting heart rate was 2.5%.
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We studied the potential modifying effects of gender, beta-blockers and calcium-channel blockers on the association of genetic variants on resting heart rate but did not observe any significant interactions (Supplementary Table 4) .
We summed the number of resting heart rate-increasing alleles, weighted for the strength of the association in the replication data set, to create a weighted genetic risk score (GRS) for each individual and evaluated associations with cardiovascular measures. Genetically determined higher resting heart rate was associated with higher body mass index and systolic and diastolic blood pressure, higher odds of hypertension, active smoking behavior and experiencing supraventricular tachycardia and lower odds of device implantation (P < 0.05; Table 3 ). Shared heritability estimates are presented in Supplementary Table 5 and indicate correlations of resting heart rate with body mass index, blood pressure, hypertension, diabetes, active smoking behavior and myocardial infarction.
In a random-effects meta-analysis of the genetic variant-specific β 3 (the putative association between resting heart rate and outcome mediated through that variant) of all hypothesis-generating loci (P < 1 × 10 −5 ) we observed a significant association between genetic variants associated with resting heart rate and all-cause mortality, translating to a relative increase of 20% in all-cause mortality risk per 5-bpm increase in resting heart rate (estimated hazard ratio (HR) = 1.20, CI = 1.11-1.28, P = 8.20 × 10 −7 ) ( Table 4 and Supplementary Fig. 4) . When the number of genetic variants was restricted stepwise from P < 1 × 10 −5 to P < 5 × 10 −8 , the HR decreased but remained significant ( Table 4) . Next, we calculated weighted and unweighted GRS and found similar associations with all-cause mortality ( Table 4) . Kaplan-Meier failure curves for all-cause mortality are shown in Supplementary Figure 5 . There was no specific cause of death driving the association (Supplementary Table 6 ). We extrapolated a relative risk to life expectancy of 1.20 using the National Life Tables of the United Kingdom (Online Methods) and estimated a reduction of 2.9 years for males and 2.6 years for females per 5-bpm increase in resting heart rate.
A conceptual figure of the potential explanations of the observed association between genetic variants of heart rate and outcome is provided in Supplementary Figure 6 . We performed several analyses to test for pleiotropic effects, identify confounders and mediators. First, we ruled out the possibility that extreme associations drive the genetic association with all-cause mortality by repeating the metaanalysis without the 12 genetic variants that showed associations with mortality at P < 0.05 (Table 4) . Second, we adjusted for resting heart rate in the Cox regression model predicting all-cause mortality. The association of the genetic variants with all-cause mortality was abolished, suggesting that the genetic association is mediated via resting heart rate ( Table 4) . Next, we adjusted for covariates observed to be associated with identified genetic variants in UK Biobank ( Table 4) . Introducing baseline body mass index, diastolic blood pressure, hypertension, diabetes, active smoking, history of heart failure, supraventricular tachycardia, myocardial infarction, device implantation, beta-blockers and calcium channel-blockers did not affect the association between the genetic variants for heart rate and all-cause mortality ( Table 4) . Further, when we excluded all genetic variants that individually showed nominal significant association in UK Biobank (P < 0.05) with any of the significant variables in Table 3 , the association between the genetic variants for heart rate and allcause mortality remained significant. Next, we considered potential confounders of variables not available in the UK Biobank cohort and performed multivariable Mendelian randomization (MR) to adjust for blood lipid levels (low-density lipoprotein, high-density lipoprotein, total cholesterol, triglycerides) and red blood cell (red blood cell count, packed cell volume, mean corpuscular volume and hemoglobin count) variables. The adjustments did not attenuate the association of the heart rate-associated genetic variants with all-cause mortality ( Table 4) . The results of the MR-Egger method confirmed the absence of evidence for directional (unbalanced) pleiotropy (Table 4) . When we used the genetic variant coefficients derived from the associations with resting heart rate when restricted to healthy individuals (Table 1) , the prediction of all-cause mortality remained similar (Table 4) , further supporting the idea that underlying diseases or heart-ratelowering medication did not confound our observation. The association with all-cause mortality also persisted when we used genetic variant coefficients estimated in the replication sample. If we extrapolate the estimates from our sensitivity analyses (ranging from 1.11 to 1.29 ( Table 4) ), this would translate to a reduction in life expectancy of 1.9-4.1 years per 5-bpm increase in resting heart rate for males and 1.8-3.7 years per 5-bpm increase in resting heart rate for females.
At 19 of 64 loci, the sentinel genetic variant or a genetic variant in linkage disequilibrium (LD; r 2 > 0.8) have reported GWAS associations. These include lipid, metabolic and blood pressure-related traits (Supplementary Table 7 ). The 64 loci were highly enriched for DNase I hypersensitive sites, marking transcriptionally active regions of the genome in human fetal heart tissue ( Fig. 2a) . Enrichment testing of expression in 209 tissue and cell types identified cardiovascular tissues and the adrenal gland to be the most relevant for our association findings ( Fig. 2b and Supplementary Table 8) . Across the 64 loci, 1,668 annotated genes are located within 1 Mb of the sentinel genetic variants. On the basis of proximity, the presence of nonsynonymous genetic variants in high LD, cis-expression quantitative trait loci (eQTL) and data-driven expression-prioritized integration for complex traits (DEPICT) 24 analyses, we prioritized rs145358377  rs272564  rs2152735  rs41317993  rs11454451  rs1260326  rs12713404  rs564190295  rs151041685  rs62172372  rs907683  rs4608502  rs13002735  rs41312411  rs3749237   rs2358740  rs1483890  rs11920570  rs7612445  rs12501032  rs6845865  rs13165531  rs35284930  rs4868243  rs236349  rs3951016  rs1320761  rs58437978  rs180239  rs17881696   rs41748  rs11563648  rs138186803  rs73158705  rs56233017  rs10739663  rs12576326  rs11320420  rs75190942  rs2283274  rs10841486  rs4963772  rs1050288  rs1994135  rs11183443  rs867400  rs12579753  rs12889267  rs422068  rs17180489  rs1549118  rs17201923  rs4900069  rs7173389  rs3915499  rs7194801  rs79121763  rs11083258  rs61735998  rs16974196  rs12721051  rs6123471  rs17265513 Figure 1 Genome-wide −log 10 (P) plot and effects for significant loci. Genome-wide −log 10 (P) plots are shown for heart rate. Blue indicates previously identified genetic variants within loci reaching genome-wide significance; red indicates novel genetic variants within loci reaching genome-wide significance (±1 Mb of lowest P value). The dashed line indicates the genome-wide significance threshold (P = 5 × 10 −8 ). Candidate genes are listed along with strategies used to identify them: n, nearest; c, coding; nonsynonymous variant; e, eQTL; d, DEPICT tool. Fig. 7 ). This work highlights the unprecedented opportunity provided by large-scale projects such as UK Biobank, the 100,000 Genomes Project 25 and the Precision Medicine Initiative 26 to discover novel genetic associations and to study links with outcomes and mortality. In this GWAS and replication study, performed in 265,046 individuals, we found 46 novel genetic loci associated with resting heart rate, increasing the total number of heart rate-associated loci to 67 (ref. 23) . Several epidemiologic studies have reported an association between higher resting heart rate and increased mortality from both cardiovascular and noncardiovascular causes [3] [4] [5] [6] [7] [8] . In all of these studies, this association was potentially confounded by differences in demographics and in physiological characteristics such as body mass index, smoking, alcohol consumption and blood pressure. Further, data from intervention trials do not provide a consistent link between heart rate reduction and improvement in clinical outcomes. Selective sinus-node inhibition with ivabradine has beneficial effects on outcomes in patients with chronic heart failure 21 but did not improve outcomes in patients with CAD 20 .
In the present work we show that genetic variants associated with higher resting heart rate confer a risk for all-cause mortality. We studied the strength of these genetic variants with mortality and studied the role of heart rate in comparison with other, potentially confounding variables closely associated with heart rate. The genetic variants identified to be associated with heart rate were also associated with potential measured (body mass index, systolic and diastolic blood pressure, hypertension, smoking, supraventricular tachycardia and device implantation) and unmeasured confounders. However, our analyses adjusting for covariates, allowing genetic variants to have pleiotropic effects, removing genetic variants associated with other a Effect estimates with 95% CI using weighted GRS (per 5-bpm increase in resting heart rate) are shown as β-estimates for quantitative variables (body mass index, systolic and diastolic blood pressure) and as odds ratios for categorical variables (hypertension, diabetes, smoking current, myocardial infarction, heart failure, atrial fibrillation or flutter, supraventricular tachycardia, device implantation, beta-blockers and calcium-channel blockers). GVs, genetic variants; adj., adjustment. a HR with 95% CI estimated with standard MR and weighted GRS per 5 bpm and for unweighted GRS per 5 summed risk alleles. b Baseline body mass index, systolic and diastolic blood pressure, hypertension, diabetes, active smoking and a history of myocardial infarction, heart failure, atrial fibrillation or flutter, supraventricular tachycardias, device implantation, beta-blockers and calcium-channel blockers. c Lipid covariates include low-den sity lipoprotein, high-density lipoprotein, total cholesterol and triglycerides. d Red blood cell covariates include red blood cell count, packed cell volume, mean corpuscular volume and hemoglobin count.
l e t t e r s traits or using estimates derived from healthy participants and independent participants consistently suggest that heart rate is linked to mortality and, by extension, to life expectancy. Indeed, only heart rate itself attenuated the association of the genetic variants with the outcome to the null. This leaves two likely possibilities: either the genetic variants exert their effect on mortality directly via heart rate as a mediator, or the genetic variants share underlying biology, resulting in increases in heart rate as well as mortality risk. Although direct specific intervention (sinus-node inhibition) on heart rate does not consistently result in reduction in mortality 20,21,27 , we hypothesize that the association originates from a shared biology not targeted by sinus-node inhibition. This could involve basic cellular biology behind heart rate and, possibly, vulnerability to cardiac arrhythmias causing (sudden) death, which might contribute to all classifications of death and might eventually also be relevant for a plethora of noncardiac diseases and conditions. This theory can be supported by the identification of predominant cardiac candidate genes at the identified loci and the colocalization of DNase hypersensitivity sites in cardiac tissue. However, alternative speculations involving basic metabolic rate, energetics and free radicals could result in cumulative general damage and affect life span 28 .
In addition to an interpretation of causation, there are several other limitations of our study that are important to acknowledge. Although recent studies 29, 30 and empirical estimates on the UK10K 31 and 1000 Genomes Project 32 support the use of a genomewide significant threshold at the level of P < 5.0 × 10 −8 , the adequacy of this value for UK Biobank has not been fully investigated. In addition, among the loci identified, a number of candidate genes have a known function relevant to cardiac conditions; however, for none of the genes have we proven that it is the mechanism for the association with heart rate or all-cause mortality. Our findings are based on statistical analyses of large data sets and do not include experimental validation of each locus to identify the underlying biological mechanisms. As with all bioinformatics analyses, the results should be interpreted as hypothesis generating and requiring of wet lab validation. In addition, the list of candidate genes provides only a first interpretation with arbitrarily defined guidelines used in the GWAS community to suggest genes for further evaluation. Heart rate is a complex trait, and the principal reason for genes to be associated does not necessarily imply a role via the cardiac pacemaker or sinus-node function. Owing to the relative short follow-up period currently available and the limited number of events, our analyses focused on all-cause mortality and a crude subdivision according to the tenth revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10). On the basis of gene and pathway analyses, differences in death due to the ICD-10 category 'circulatory system' might be expected to account for the association with all-cause mortality, but this was not observed. The reason that no association was observed with 'circulatory system' remains unknown, but it might be due to heterogenic causes of death within each category; deaths in other categories might be influenced by the heart but not attributed to it. As more subjects are genotyped and long-term follow-up data become available, future analyses may allow further differentiation within each ICD-10 category to study associations of resting heart rate with specific causes of death.
In conclusion, in this GWAS we identified 46 novel loci associated with resting heart rate. The loci identified as influencing resting heart rate are also implicated in overall mortality (and, consequently, life expectancy) and therefore warrant further research into the underlying mechanisms.
URLs. Information on genotyping and quality control for UK Biobank, http://www.ukbiobank.ac.uk/wp-content/uploads/2014/04/ UKBiobank_genotyping_QC_documentation-web.pdf; ICD-10, http://apps.who.int/classifications/icd10/browse/2016/en; UK Office of National Statistics, http://www.ons.gov.uk.
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Populations. Discovery. To identify genetic variants associated with resting heart rate, we analyzed 134,251 participants from the UK Biobank. The UK Biobank recruited persons aged 40-69 years who were registered with a general medical practitioner within the UK National Health Service (NHS). In total, the study recruited 503,325 individuals between 2006 and 2010. The study has approval from the North West Multi-center Research Ethics Committee, and all participants provided informed consent. Detailed methods used by UK Biobank have been described elsewhere 22 . For sensitivity analyses we defined a subgroup of healthy individuals who were free of any (prevalent or incident) disease(s) and diagnosis and confirmed they were not using heart rate-modifying medication (beta-blockers or calcium-channel blockers (N = 11,405) ).
Replication. Replication of genome-wide significant lead SNPs was undertaken in the meta-analyzed data of 130,795 individuals derived from 23andMe, deCODE, PREVEND and LifeLines sample collections (Supplementary Table 14) .
Ascertainment of resting heart rate. As detailed in the Supplementary Note, resting heart rate in UK Biobank was assessed by two methods: an automated reading during blood pressure measurement (in 501,340 participants) and during arterial stiffness measurement using the pulse waveform obtained from the finger with an infrared sensor (in 170,790 participants). Multiple measurements for one individual were averaged. . Imputed genotype data were provided by UK Biobank on the basis of merged UK10K and 1000 Genomes phase 3 panels produced by the Wellcome Trust Centre for Human Genetics, resulting in 72,355,667 SNPs, short indels and large structural variants. Quality control for genotyping was performed before analysis and has been described in detail elsewhere 34 . We excluded variants with minor allele frequency of <0.001 and information measure <0.3, leaving 19,941,912 variants for the analyses. Samples were excluded from the analyses if they had at least one related sample (N = 17,308) on the basis of genetic-relatedness factor data and high missingness or excess heterozygosity (N = 480). A flow diagram of sample sizes after exclusion of participants is provided in Supplementary Figure 8. Statistical analysis. A GWAS was performed using SNPTEST with 19,941,912 genotyped or imputed genetic variants and resting heart rate in 134,251 individuals of UK Biobank using linear regression assuming an additive genetic model. Covariates included in the model were age, age 2 , sex, the first 10 principal components and genotyping array. Independent genetic loci were defined as 1 Mb at either side of the genetic variant that showed the strongest association in a given locus and pairwise LD r 2 < 0.1. The strongest associated variant (lowest P value) within a locus with at least one genetic variant at P < 5 × 10 −8 was designated the sentinel genetic variant. Replication of these variants was undertaken in the 23andMe, deCODE, Prevend and LifeLines cohorts using fixed-effects meta-analysis by inverse variance weighting (Supplementary Table 14 ). An association was considered replicated if (i) the direction of effect was concordant, (ii) the replication P < 0.025 (one-way), and (iii) meta-P < 5 × 10 −8 . For detecting secondary associations not explained by the sentinel genetic variant at each locus, we repeated the GWAS including all sentinel genetic variants (P < 5 × 10 −8 ) as covariates in a conditional analysis. Potential modifier effects of participant sex and use of beta-blockers or calcium-channel blockers on resting heart rate were assessed by an interaction test (Bonferroni adjusted for the number (n) of tests (P < 0.05/n)).
Ascertainment of cardiovascular events and mortality. The prevalence and incidence of cardiovascular risk factors (Supplementary
We used genetic variants as instrumental variables to study the relationship of resting heart rate with outcomes (MR). To this end, we defined a larger set of independent loci at the previously specified hypothesis-generating threshold (P < 1 × 10 −5 ) to increase power 35, 36 . For our main analysis we calculated the putative association between resting heart rate (per 5 bpm) and outcome mediated through that variant (β 3 values) from the direct measurements of the effect size of the association between the variant and resting heart rate (β 1 ) and the effect size of the association between the variant and outcome (β 2 ), as described previously 37 . The value of β 3 can be interpreted as the HR for outcome per 5-bpm increase in genetically determined resting heart rate. Inverse-variance-weighted random-effects meta-analysis was used to combine individual β 3 estimates, providing additional power to assess the overall association between genetically determined resting heart rate and mortality. Cochran's Q statistic was used to assess heterogeneity among β 3 estimates. We also created a weighted GRS by first multiplying for each individual the effect size of the association between the variant and resting heart rate (β 1 ) with the number of alleles 0-2 of each genetic variant and then summing all products. An unweighted GRS was created by summing the number of resting heart rate-increasing alleles 0-2 of each associated genetic variant.
To examine the robustness of our findings as well as the possibility of pleiotropic or other confounding and mediation effects, we included covariates and the phenotype resting heart rate into Cox regression models. We excluded all genetic variants that were also individually nominally associated (P < 0.05) with covariates, performed multivariable Mendelian randomization 38 to account for variables not available in UK Biobank and used the MR-Egger regression method to test for evidence of pleiotropy 39 (Supplementary Note and Supplementary Figs. 9 and 10) . As an alternative strategy to exclude confounding due to prevalent disease or medication use, we estimated the associations of each genetic variant with resting heart rate (β 1 ) in the subgroup of 11,405 healthy individuals (defined above) to calculate the HR for outcome. We estimated the impact on life expectancy using the National Life Tables of the United Kingdom provided by the Office of National Statistics of 2011-2013 separately for males and females (Supplementary Note).
Details of analyses performed to gain insights in the biological pathways and tissues underlying the genome-wide significant loci are provided in the Supplementary Note. Data availability. The GWAS discovery data that support the findings of this study are available at http://www.cardiomics.net/download-data. Replication data (Supplementary Table 14) are available in Supplementary Table 2 . All other data generated or analyzed during this study are included with this article.
